Fisher Asset Management LLC boosted its stake in shares of Ligand Pharmaceuticals by 280.7% in the 3rd quarter.

Source: https://www.etfdailynews.com/2023/02/24/amalgamated-bank-has-620000-holdings-in-ligand-pharmaceuticals-incorporated-nasdaqlgnd-2/

Ligand owns a tiered royalty of up to 2.6% on the drug, it successfully commercialized as well as up to 86 million of milestones.

Source: https://seekingalpha.com/article/4649530-ligand-pharmaceuticals-inc-lgnd-q3-2023-earnings-call-transcript?source=feed_all_articles

Roth Capital lifted their price objective on Ligand Pharmaceuticals from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, December 23rd.

Source: https://www.etfdailynews.com/2023/01/25/comerica-bank-reduces-stake-in-ligand-pharmaceuticals-incorporated-nasdaqlgnd/

Turning now to our financial results, as a reminder OmniAb was part of Ligand for the first 10 months of the year.

Source: https://seekingalpha.com/article/4591785-omniab-inc-oabi-q4-2022-earnings-call-transcript?source=feed_all_articles